United States newsroom

Babs is sharing her family’s history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical...

Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy...

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their...

Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug...

FOR IMMEDIATE RELEASE – NORTHBROOK, IL, Dec. 23, 2024 – Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") is voluntarily recalling one lot of PROGRAF® 0.5mg...

"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives. NORTHBROOK, Ill., Dec. 5, 2024 /PRNewswire/ -- Astellas Pharma...

SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare...

ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today...

The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners

- Collaboration to focus on gene therapy research for the treatment of ultra-rare disease NORTHBROOK, Ill., June 20, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today the...

Community-driven collaboration aims to raise awareness of the value PAOs offer patients and their caregivers NORTHBROOK, Ill., June 10, 2024 /PRNewswire/ -- Astellas is proud to announce that it...

- 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and business development operations TOKYO and SAN FRANCISCO, May 8,...

Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today...

Designation follows December 2023 FDA approval for the treatment of these serious, potentially life-threatening fungal infections in children CRESEMBA receives seven years and six months of US...

NORTHBROOK, Ill., Feb. 22, 2024 /PRNewswire/ -- Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the...

Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms1 The "Fewer Hot Flashes, More Not Flashes"

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco, CA, along with the invaluable expertise provided by Astellas to advance...

CRESEMBA is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections Approval based on results of two...

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...

If approved, CRESEMBA will offer a new treatment option for pediatric patients facing certain invasive fungal infections NORTHBROOK, Ill., Aug. 10, 2023 /PRNewswire/ -- Astellas Pharma US, Inc....

Both Companies win a year of access to a prestigious life-science incubator in San Francisco, CA and to Astellas expertise to further their research Award helps biotech start-ups accelerate early...

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ --...

- Winner developed app to empower cancer patients after experience as a cancer caregiver - NORTHBROOK, Ill., Aug. 8, 2022 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the...

- 135,000 square-foot state-of-the-art gene therapy manufacturing facility located in Sanford, N.C., officially opened June 8 - Facility to support clinical- and commercial-scale manufacturing of...

- Addressing everyday challenges in cancer care; apply by June 3, 2022 - NORTHBROOK, Ill., April 25, 2022 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced that it is accepting...

- Vcreate and Weatherwax Biotechnologies win a year of access to life-science incubator in San Francisco, CA and to Astellas expertise to further their research - TOKYO and SAN FRANCISCO, Dec. 14,...

-Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research- CAMBRIDGE, Mass., Nov. 3, 2021 /

Astellas ranked again in Seramount's 100 Best Companies and Best Companies for Dads lists. NORTHBROOK, Ill., Sept. 28, 2021 /PRNewswire/ -- Seramount (formerly Working Mother Media) revealed its...

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ --...

Astellas' "Future Innovator Prize" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas CAMBRIDGE, Mass., Aug....

- PROGRAF Becomes First Immunosuppressive Drug Approved in the U.S. for People Receiving a Lung Transplant - NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,...

- Three innovators awarded $200,000 in total grants and resources for their work to "Change Cancer Care" beyond medicine - NORTHBROOK, Ill., March 24, 2021 /PRNewswire/ -- Astellas Pharma US, Inc....

Oncology head Mark Reisenauer named Astellas US President; Masahide Goto named President at Astellas Institute for Regenerative Medicine NORTHBROOK, Ill. and BOSTON, Feb. 4, 2021 /PRNewswire/ --...

NORTHBROOK, Ill., Jan. 28, 2021 /PRNewswire/ -- For the seventh consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's (HRC) annual Corporate Equality Index

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise SAN FRANCISCO, Dec. 14, 2020 /PRNewswire/ -- Astellas Venture Management (President:...

- AXONIS Therapeutics, Inc. and Tenza win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research - CAMBRIDGE, Mass., Oct. 8, 2020...

- 11th Annual Changing Tomorrow Day Enables Employees to Support Frontline Workers in Hospitals, Homeless and Hospitalized Veterans and Others in Need - NORTHBROOK, Ill., Oct. 1, 2020 /PRNewswire/...

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 29, 2020 /PRNewswire/ --...

NORTHBROOK, Ill., Sept. 23, 2020 /PRNewswire/ -- Astellas today announced the structure and operating model for its global Patient Centricity organization designed to support the development of...

NORTHBROOK, Ill., Sept. 15, 2020 /PRNewswire/ -- Astellas again ranked among the top companies for working parents in Working Mother Magazine's 2020 "100 Best Companies" list for both working...

Recent grants and redirected funding help to respond to the COVID-19 pandemic by improving healthcare infrastructure, training and education in low-income countries NORTHBROOK, Ill., Sept. 1, 2020...

-Tackling everyday challenges in cancer care, apply by September 28, 2020- NORTHBROOK, Ill., Aug. 4, 2020 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the call for entries...

Astellas "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas CAMBRIDGE, Mass., July 23, 2020...

NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration...

NORTHBROOK, Ill., April 30, 2020 /PRNewswire/ -- With more and more Americans facing economic hardships as a result of the COVID-19 pandemic, Astellas has implemented changes to its patient...

- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need - NORTHBROOK, Ill. and INDIANAPOLIS, Feb. 10, 2020 /PRNewswire/ -- The Astellas Global...

NORTHBROOK, Ill., Jan. 21, 2020 /PRNewswire/ -- For the sixth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's (HRC) annual Corporate Equality...

NORTHBROOK, Ill., Jan. 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for...